Share your email to get news and updates!

Recent News


Newly Identified Lipid in Breast Milk Might Reduce Cerebral Palsy in Infants

DURHAM, N.C., August 2023 (Duke University Office of Translation and Commercialization) – The study appears Aug. 3 in the journal Cell Stem Cell. Eric Benner, M.D., Ph.D., is the study’s corresponding author and is a distinguished assistant professor in the Department of Pediatrics at Duke University School of Medicine.

tellus, xontogeny, perceptive logos

Tellus Therapeutics Announces $35 Million Series A Financing

DURHAM, NC, December 13, 2022 (Business Wire) – Tellus Therapeutics, a neonatal care company developing treatments for newborns in the neonatal intensive care unit (NICU), announced today the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The capital will be used to continue important preclinical work conducted through the seed investment with the Xontogeny development team and to advance TT-20, the company’s lead candidate for the treatment of white matter brain injury in preterm infants, as well as the company’s pipeline programs.


For neurological disorders, milk-based therapies are on the way

November 10th, 2022 (Drug Discovery News) – A mammal’s first source of nutrients comes from milk. Filled with proteins, sugars, lipids, antibodies, cells, hormones and prebiotics, milk provides the necessary nourishment to help babies develop into healthy adults (1). But scientists have discovered that milk components are not just important for child development; they can have therapeutic effects too.

tellus and xontogeny logos2

Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury

DURHAM, N.C, May 12, 2021 –(BUSINESS WIRE)– Tellus Therapeutics, Inc., a biopharmaceutical company developing TT-20 as a treatment for white matter injury (WMI) and myelin repair in premature babies, today announced a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling work.


Tellus Therapeutics Awarded NINDS SBIR Funding for Development of TT-20 for Treatment of Neonatal Brain Injury

DURHAM, NC, UNITED STATES, December 7, 2020 — Tellus Therapeutics today announced the award of a Phase 1 NINDS SBIR grant of $696,000 to fund further preclinical development of TT-20.


Tellus Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations

DURHAM, NORTH CAROLINA, October 21, 2020 — Tellus Therapeutics today announced that the U.S. FDA granted Orphan Drug and Rare Pediatric Drug designations for Neonatal Brain Injury Program TT-20.

SAB members

Tellus Therapeutics Announces Appointments to Scientific Advisory Board

DURHAM, NORTH CAROLINA, UNITED STATES, October 5, 2020 — Tellus Therapeutics today announced the appointment of Drs. Terrie Inder and Chi Hornik to the Scientific Advisory Board (SAB).

Portrait of newborn baby and hand inside incubator

Tellus Therapeutics – Traction in 2020

March 11th, 2020

Tellus Therapeutics is on target for a productive 2020 and is gaining traction towards its mission of developing treatments for unmet needs in newborns.

From L to R: Ed Field of BioLabs NC, Dr. Eric Benner,
Dr. Tarun Saxena of Duke CTSI Accelerator,
and Dr. Barry Myers.

First Ever Golden Ticket Awarded to Dr. Eric Benner

December 10, 2019

Duke Clinical & Translational Science Institute and BioLabs North Carolina have awarded the first ever Duke Golden Ticket to Dr. Eric Benner, Assistant Professor of Pediatrics in the Duke School of Medicine, and co-founder of Tellus Therapeutics.


MassChallenge Startup Competition Winner Uses Breast Milk to Fight Cerebral Palsy

Andy Rosen, Boston Globe Staff – October 24, 2019

A North Carolina startup that uses molecules from breast milk to help prevent cerebral palsy took home a $100,000 grant Thursday night, the top prize in the annual awards program carried out by MassChallenge, a nonprofit accelerator program for promising businesses.